"Designing Growth Strategies is in our DNA"

Transcranial Magnetic Stimulation Devices Market Size, Share & Industry Analysis, By Product Type, By Application, By End-user, and Regional Forecast, 2026-2034

Last Updated: November 19, 2026 | Format: PDF | Report ID: FBI119767

 

Transcranial Magnetic Stimulation Devices Market Size and Future Outlook

Play Audio Listen to Audio Version

The global transcranial magnetic stimulation devices market size was valued at USD 327.6 million in 2025. The market is projected to grow from USD 367.9 million in 2026 to USD 846.3 million by 2034, exhibiting a CAGR of 11.0% during the forecast period.

Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technology in which a coil placed near the scalp generates rapidly changing magnetic fields. These fields induce electrical currents in targeted cortical regions and alter neuronal activity. The global market growth is driven primarily by the rising prevalence of mental health and neurological conditions globally.

Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim held the highest market share in 2025 due to their strong product portfolio and strategic initiatives such as acquisitions, partnerships, collaborations, and others.

Shift Toward Multi-indication, Connected, and Navigation-enabled Platforms to Emerge as a Key Trend

Currently, TMS systems are becoming more flexible and capable of supporting multiple uses on a single platform due to advancements. Moreover, newly introduced systems combine treatment protocols with navigation, data tracking, different coil options, software-guided workflows, and diagnostic or research applications.

  • For instance, in October 2025, Nexstim launched diagnostic applications for its NBS 6 system in the U.S., incorporating motor and speech mapping capabilities alongside therapy applications.

This shift is increasing demand for navigation, software, coils, and accessories, which are expected to expand more significantly than the core TMS stimulator systems.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Expanding Depression Burden and Treatment Demand to Drive Market Growth

Over the past few years, there have been an increasing number of cases of depression worldwide. For instance, in September 2026, the World Health Organization (WHO) stated that around 322.0 million people experienced depression in 2023, representing about 5.2% of adults.

This large patient pool is contributing to the expansion of TMS clinics, new system installations, and higher treatment volumes. Moreover, demand is particularly driven by patients who do not respond well to medication, prefer non-drug treatment options, or have access to reimbursed TMS therapy. Such a scenario is anticipated to drive the market growth during the forecast period.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Expected Impact on Market Growth Estimated Gross Market Growth Contribution (USD Million) Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Expanding depression burden and treatment demand High 180.0 High High High
2 Expansion of reimbursement, payer coverage and TMS clinic access High 135.0 High High High
3 Accelerated, theta-burst and higher-throughput treatment protocols Medium-High 110.0 Medium High High
4 New indications, adolescent use and precision/navigation-enabled TMS Medium-High 85.0 Medium High High
5 Emerging-market mental-health infrastructure and local manufacturing Medium 65.0 Medium Medium Medium
6 Others (replacement cycles, leasing models, research demand, workflow software) Low 40.0 Low Low Low
Total Gross Growth Contribution 615  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET RESTRAINTS

High Equipment Costs and Uneven Reimbursement to Restrict Market Growth

Despite growing treatment demand, TMS adoption is limited by the high cost of equipment, treatment space, trained staff, and repeated patient visits. Additionally, reimbursement is available in some developed markets, but coverage varies by country. For instance, the World Health Organization (WHO) reported in 2025 that mental health receives only about 2.0% of global health budgets, while many countries also face shortages of mental-health professionals.

These funding and workforce gaps are expected to slow the adoption of TMS, particularly in lower-income and less-developed healthcare markets. Such a scenario is anticipated to hinder the market growth over the forecast period.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Expected Impact on Market Growth Estimated Reduction in Market Size (USD Million)
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 High equipment costs and uneven reimbursement High 55.0 High High Medium
2 Shortage of trained mental-health / TMS professionals and clinic capacity Medium-High 37.0 High Medium Medium
3 Clinical-response variability and evidence/regulatory requirements for new indications Medium 29.0 Medium Medium Medium
4 Others (competition from substitutes, price pressure, workflow and cybersecurity requirements) Low 15.6 Low Low Low
Total Market Reduction 136.6  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Accelerated and Precision TMS Workflows to Create Lucrative Opportunities

Accelerated and precision TMS protocols shorten treatment schedules and improve targeting accuracy. This makes treatment more convenient for patients while allowing clinics to treat more patients using the same equipment.

  • For instance, in May 2026, MagVenture received FDA clearance for accelerated TMS protocols for adult MDD, enabling multiple sessions per day.

These advances are expected to create significant opportunities for higher clinic efficiency, greater system utilization, and wider adoption, especially where reimbursement supports newer treatment approaches. This is expected to fuel the market expansion in the near future.

MARKET CHALLENGES

Clinical Response Variability and Evidence Requirements to Challenge Market Expansion

Transcranial magnetic stimulation (TMS) devices do not work equally well for each patient, and treatment outcomes vary based on the condition, protocol, targeting method, and previous treatments.

Moreover, the focus of key players on expanding TMS into new indications and patient groups is driving the need for strong clinical evidence to support safety and effectiveness. This is expected to increase clinical trial costs, regulatory timelines, and commercialization risk. Henceforth, several emerging TMS applications remain limited to research until they receive regulatory approval and gain wider clinical adoption. This is anticipated to challenge the transcranial magnetic stimulation devices market growth during the forecast period.

Segmentation Analysis

By Product Type

Large Installed Base of TMS Stimulator Systems to Support Segment’s Growth

Based on product type, the market is segmented into TMS stimulator systems, TMS coils, navigation, mapping & positioning systems, TMS-specific accessories & consumables, and others.

The TMS stimulator systems segment accounted for the largest global transcranial magnetic stimulation devices market share in 2025 because it is the main capital equipment purchased by treatment centers. This leads to an overall higher installed based globally, contributing to the segment’s growth.

  • For instance, at the end of 2025, BrainsWay reported a total installed base of approximately 1,700 Deep TMS systems.

To know how our report can help streamline your business, Speak to Analyst

The TMS coils segment is projected to grow at an 11.7% CAGR during the forecast period.

By Application

Increasing Number of Depression Patients to Support Depressive Disorders Segment’s Growth

By application, the market is classified into depressive disorders, obsessive-compulsive disorder, addiction & substance-use disorders, neurological & pain management, cortical mapping & pre-surgical planning, and research & other applications.

The depressive disorders segment accounted for the largest market share in 2025. The segment’s growth is attributed to an increasing number of depression patients globally, which is an established indication for TMS devices. Moreover, the segment is set to acquire a 62.4% share in 2026.

  • For instance, in January 2026, Crownview Psychiatric Institute stated that around 21.5 million people over age 18 in the U.S. have depression.

The obsessive compulsive disorder segment is expected to grow at a CAGR of 12.5% during the forecast period.

By End-user

Higher Capability to Treat Patients With TMS to Fuel the Hospitals & Health Systems Segment’s Growth

On the basis of end-user, the market is segmented into hospitals & health systems, independent psychiatric & TMS clinics, independent neurology & neurosurgery centers, universities & research institutes, and others.

In 2025, the hospitals & health systems segment dominated the market due to their higher capability of these settings to treat depression and OCD patients, which is expected to drive the demand for TMS devices. Furthermore, the segment is set to hold a 47.4% market share in 2026.

The independent psychiatric & TMS clinics segment is projected to grow at a CAGR of 11.7% during the forecast period.

Transcranial Magnetic Stimulation Devices Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America Transcranial Magnetic Stimulation Devices Market Size, 2025 (USD Million)

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share in 2024, valued at USD 134.9 million. It maintained its leading position in 2025, with USD 150.7 million, primarily due to the higher treatment rate of depression and product penetration in the U.S. and Canada. Additionally, favorable reimbursement coverage for eligible patients and the expansion of outpatient mental health treatment centers are contributing to the adoption of TMS devices across the region.

  • For instance, according to the data published by the American Hospital Association in September 2025, nearly 48.0 million U.S. individuals are currently being treated for depression.

U.S. Transcranial Magnetic Stimulation Devices Market

In 2026, the U.S. market is anticipated to reach USD 155.3 million, accounting for approximately 42.2% of the global sales.

Europe

Europe is projected to record a CAGR of 9.2% during the forecast period, the third-highest globally. The market is expected to reach USD 81.2 million in 2026. The region’s growth is attributed to the presence of key players and strong healthcare infrastructure supporting the adoption of Transcranial Magnetic Stimulation (TMS) devices.

U.K. Transcranial Magnetic Stimulation Devices Market

The U.K. market is projected to reach USD 12.6 million in 2026, representing approximately 3.4% of global sales.

Germany Transcranial Magnetic Stimulation Devices Market

Germany's market is expected to reach USD 14.0 million in 2026, accounting for approximately 3.8% of global revenues.

Asia Pacific

In 2026, the market in Asia Pacific is projected to reach approximately USD 94.2 million, making it the second-largest market. The region’s growth is due to a large patient pool of neurological disorders in India, Japan, and China, which is expected to fuel the adoption of transcranial magnetic stimulation devices.

Japan Transcranial Magnetic Stimulation Devices Market

Japan’s market is projected to reach approximately USD 17.7 million in revenue in 2026, representing nearly 4.8% of the global sales.

China Transcranial Magnetic Stimulation Devices Market

In 2026, China’s market is anticipated to reach USD 36.2 million, accounting for approximately 9.9% of the global sales.

India Transcranial Magnetic Stimulation Devices Market

In 2026, India’s market is anticipated to reach USD 7.8 million, accounting for approximately 2.1% of the global sales.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are anticipated to witness moderate growth during the forecast period. The Latin America market is estimated to reach approximately USD 14.3 million in 2026. Latin America’s growth is supported by expanding private mental health services, which is offering significant opportunity for transmagnetic stimulation device adoption. Moreover, the market growth of the Middle East & Africa is mainly attributed to increasing healthcare infrastructure investment and key professionals, which is expected to influence key players to increase product penetration in this region.

GCC Transcranial Magnetic Stimulation Devices Market

In 2026, the GCC market is estimated to reach approximately USD 4.6 million, representing around 1.2% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Brand Image, Investments, and Geographic Expansion Focus of Major Companies to Increase their Market Share

Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim are prominent players in the global transcranial magnetic stimulation devices market. The dominance of these companies is attributed to their strong R&D investments, product launches, and brand image of the company in offering TMS systems.

Moreover, other prominent players are focusing on geographic expansion and strengthening distribution networks in emerging countries. This is expected to improve their market share in the forthcoming years.

LIST OF KEY TRANSCRANIAL MAGNETIC STIMULATION DEVICES COMPANIES PROFILED IN REPORT

  • Neuronetics (U.S.)
  • BrainsWay (Israel)
  • MagVenture A/S (Denmark)
  • Magstim (U.K.)
  • Nexstim (Finland)
  • MAG & More GmbH (Germany)
  • Neurosoft (Russia)
  • Shenzhen Yingchi Technology Co., Ltd. (China)
  • REMED (South Korea)
  • DEYMED Diagnostic s.r.o. (Czech Republic)

KEY INDUSTRY DEVELOPMENTS

  • March 2026: Soterix Medical received FDA 510(k) clearance (K251653) for its SPRY TMS Therapy System to treat adult major depressive disorder.
  • October 2025: Nexstim launched NBS 6 diagnostic applications in the U.S., adding modular motor-speech mapping capabilities.
  • September 2025: MagVenture A/S announced FDA clearance expanding one-coil use across MDD, OCD, and anxious depression configurations.
  • May 2025: Yiruide announced an NMPA Class III registration certificate for a TMS system indicated for depression in China.
  • May 2025: Shenzhen Yingchi Technology Co., Ltd. announced FDA clearances for rTMS in OCD and iTBS in MDD (K243459/K243460).
  • March 2024: Neuronetics received FDA clearance for NeuroStar as an adjunct treatment for MDD in adolescents aged 15-21.

REPORT COVERAGE

The report offers detailed analysis of the global transcranial magnetic stimulation devices market across its key segments. It covers the major drivers, restraints, opportunities, challenges, and trends contributing to market growth. The study further examines the prevalence of depression, technological advancements, recent industry developments, competitive analysis, company market share analysis, and detailed profiles of major companies operating in the market.

Request for Customization   to gain extensive market insights.


Report Scope & Segmentation

ATTRIBUTE  DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 11.0% from 2026-2034
Unit Value (USD Million)
Segmentation By Product Type, Application, End-user, and Region
By Product Type
  • TMS Stimulator Systems
  • TMS Coils
  • Navigation, Mapping & Positioning Systems
  • TMS-specific Accessories & Consumables
  • Others
By Application
  • Depressive Disorders
  • Obsessive Compulsive Disorder
  • Addiction & Substance-Use Disorders
  • Neurological & Pain Management
  • Cortical Mapping & Pre-Surgical Planning
  • Research & Other Applications
By End-user
  • Hospitals & Health Systems
  • Independent Psychiatric & TMS Clinics
  • Independent Neurology & Neurosurgery Centers
  • Universities & Research Institutes
  • Others
By Region
  • North America (By Product Type, Application, End-user, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Product Type, Application, End-user, and Country/Sub-region)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Spain (By Application)
    • Italy (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Product Type, Application, End-user, and Country/Sub-region)
    • China (By Application)
    • Japan (By Application)
    • India (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Product Type, Application, End-user, and Country/Sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Product Type, Application, End-user, and Country/Sub-region)
    • GCC (By Application)
    • South Africa (By Application)
    • Rest of the Middle East & Africa (By Application)

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major TMS Players

  • Collection of TMS-attributable revenues from annual reports, SEC filings, investor presentations, company disclosures, and product portfolios of key manufacturers such as Neuronetics, BrainsWay, MagVenture, Magstim, Nexstim, Yiruide, Yingchi, and others.
  • Assessment of system sales, installed base, annual placements, geographic presence, regulatory clearances, distribution network, and end-user penetration.
  • Triangulation of manufacturer revenues with regional and country-level demand indicators to estimate the global market.

Approach 2: Installed Base, Unit Sales & ASP Analysis

  • Estimation of installed TMS systems, annual new placements, replacement/upgrade demand, and separately sold coils, navigation systems, and accessories.
  • Analysis of manufacturer selling prices for therapeutic TMS systems, research/diagnostic systems, neuronavigated platforms, coils, and accessories.
  • Calculation of country-level market value using annual unit demand × manufacturer ASP, followed by aggregation to regional and global levels.

Approach 3: Treatment Volume & Utilization Model

  • Assessment of TMS-treated patient volumes across depression, OCD, neurological/pain applications, cortical mapping, and other indications.
  • Analysis of treatment sessions per patient, annual system utilization, TMS clinic density, psychiatric/neurology infrastructure, and eligible patient populations.
  • Translation of treatment demand into required installed systems, recurring equipment-linked revenues, and country-level device demand.

2. Top Down Approaches

Approach 4: Analysis of Parent Neuromodulation & Medical Device Markets

  • Analysis of broader neuromodulation, neurostimulation, psychiatric-device, and medical-device spending across key countries.
  • Estimation of the proportion attributable to non-invasive TMS devices based on installed base, clinical adoption, indication coverage, healthcare infrastructure, and reimbursement.
  • Validation of top-down estimates against manufacturer revenues, unit placements, treatment volumes, and country-level TMS penetration.

3. List of Key Sources

  • FDA
  • European Commission / EU MDR
  • PMDA / MHLW
  • NMPA
  • CDSCO
  • TGA
  • WHO
  • OECD
  • Eurostat
  • World Bank
  • Clinical TMS Society
  • International Federation of Clinical Neurophysiology
  • Medical-device and neuromodulation associations
  • Annual reports and SEC filings
  • Investor presentations and earnings releases
  • Company product catalogs and regulatory filings
  • Regulatory approvals and new indication clearances
  • Product launches and system-placement announcements
  • Reimbursement and coverage updates
  • Hospital/TMS clinic expansion
  • Published clinical studies and treatment guidelines

4. Primary Interviews

Supply Side Interviews: 60%

  • Key Respondents:
    • TMS device manufacturers, distributors, dealers, product managers, sales executives, marketing managers, regional business heads, and neuromodulation industry experts.
    • Discussions focus on market size, annual system placements, ASPs, installed base, replacement cycles, product mix, distribution, competitive positioning, and regional adoption.

Demand Side Interviews: 40%

  • Key Respondents:
    • Psychiatrists, neurologists, neurosurgeons, TMS clinic operators, hospital procurement professionals, researchers, and academic institutions.
    • Discussions focus on TMS adoption, treatment volumes, preferred systems, utilization levels, reimbursement, purchasing criteria, clinical applications, and country-level demand trends.


Frequently Asked Questions

Fortune Business Insights says that the global market value stood at USD 327.6 million in 2025 and is projected to reach USD 846.3 million by 2034.

In 2025, the North America’s market value stood at USD 150.7 million.

The market is expected to exhibit a CAGR of 11.0% during the forecast period.

By product type, the TMS stimulator systems segment led the market.

The key factors driving the market are the expanding depression burden and treatment demand.

Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim are the top players in the market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 250
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann